{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:11:23Z","timestamp":1789567883722,"version":"build-2803163510"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.108935","type":"journal-article","created":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T11:10:39Z","timestamp":1655637039000},"page":"108935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases"],"prefix":"10.1016","volume":"110","author":[{"given":"Dongfu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1749-6789","authenticated-orcid":false,"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.108935_b0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.108935_b0010","doi-asserted-by":"crossref","first-page":"9056173","DOI":"10.1155\/2018\/9056173","article-title":"Prospects of IL-2 in Cancer Immunotherapy","volume":"2018","author":"Choudhry","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.intimp.2022.108935_b0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4049\/jimmunol.141.3.849","article-title":"Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones","volume":"141","author":"Paliard","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0020","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ni0901-882","article-title":"Inducible IL-2 production by dendritic cells revealed by global gene expression analysis","volume":"2","author":"Granucci","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0025","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.4049\/jimmunol.172.8.4691","article-title":"Preferential activation of an IL-2 regulatory sequence transgene in TCR gamma delta and NKT cells: subset-specific differences in IL-2 regulation","volume":"172","author":"Yui","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0030","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.immuni.2011.07.013","article-title":"Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis","volume":"35","author":"Hershko","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0035","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108935_b0040","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"JCO"},{"key":"10.1016\/j.intimp.2022.108935_b0045","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0050","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","article-title":"In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2","volume":"135","author":"Lotze","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(93)80067-O","article-title":"Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene","volume":"75","author":"Sadlack","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.108935_b0060","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/1074-7613(95)90180-9","article-title":"Interleukin-2 receptor \u03b1 chain regulates the size and content of the peripheral lymphoid compartment","volume":"3","author":"Willerford","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0065","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1126\/science.7770771","article-title":"Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta","volume":"268","author":"Suzuki","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.108935_b0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/imr.12163","article-title":"The importance of regulatory T-cell heterogeneity in maintaining self-tolerance","volume":"259","author":"Yuan","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2022.108935_b0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/JLB.2RI0717-278R","article-title":"Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies","volume":"103","author":"Mitra","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2022.108935_b0080","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: biology, design and application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0085","doi-asserted-by":"crossref","first-page":"e1277306","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","author":"Klein","year":"2017","journal-title":"Oncoimmunology 6"},{"key":"10.1016\/j.intimp.2022.108935_b0090","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.intimp.2019.03.064","article-title":"New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases","volume":"72","author":"Xu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108935_b0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.intimp.2018.01.042","article-title":"Fine tuning subsets of CD4(+) T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases","volume":"56","author":"Zhao","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108935_b0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0092-8674(93)90152-G","article-title":"The IL-2\/IL-2 receptor system: a current overview","volume":"73","author":"Taniguchi","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.108935_b0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.24.021605.090616","article-title":"Structural biology of shared cytokine receptors","volume":"27","author":"Wang","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108935_b0110","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.0511161103","article-title":"Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor","volume":"103","author":"Stauber","year":"2006","journal-title":"PNAS"},{"issue":"5187","key":"10.1016\/j.intimp.2022.108935_b0115","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1126\/science.7973659","article-title":"Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits>","volume":"266","author":"Miyazaki","year":"1994","journal-title":"Science 266"},{"key":"10.1016\/j.intimp.2022.108935_b0120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4049\/jimmunol.178.1.280","article-title":"IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells","volume":"178","author":"Burchill","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2008.03.002","article-title":"The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2)","volume":"31","author":"Lan","year":"2008","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2022.108935_b0130","doi-asserted-by":"crossref","first-page":"e0167215","DOI":"10.1371\/journal.pone.0167215","article-title":"Marakhova, II, Time-Dependent Regulation of IL-2R alpha-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes","volume":"11","author":"Shatrova","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108935_b0135","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1073\/pnas.93.5.2077","article-title":"Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation","volume":"93","author":"Friedmann","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.intimp.2022.108935_b0140","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4049\/jimmunol.180.1.222","article-title":"Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation","volume":"180","author":"Pei","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0145","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0150","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0155","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2009.05.014","article-title":"Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties","volume":"31","author":"Rutishauser","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0160","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.immuni.2009.06.021","article-title":"Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses","volume":"31","author":"Kallies","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0165","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.108935_b0170","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni.2030","article-title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages","volume":"12","author":"Liao","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0175","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1073\/pnas.0400339101","article-title":"Interleukin 2 plays a central role in Th2 differentiation","volume":"101","author":"Cote-Sierra","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.intimp.2022.108935_b0180","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1073\/pnas.1301138111","article-title":"Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression","volume":"111","author":"Liao","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.intimp.2022.108935_b0185","doi-asserted-by":"crossref","unstructured":"A. Laurence, C.M. Tato, T.S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R.B. Blank, F. Meylan, R. Siegel, L. Hennighausen, E.M. Shevach, J. O'Shea J, Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation, Immunity 26 (2007) 371\u2013381. 10.1016\/j.immuni.2007.02.009.","DOI":"10.1016\/j.immuni.2007.02.009"},{"key":"10.1016\/j.intimp.2022.108935_b0190","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.immuni.2012.02.012","article-title":"Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation","volume":"36","author":"Ballesteros-Tato","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0195","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.4049\/jimmunol.171.12.6323","article-title":"The regulatory T cell family: distinct subsets and their interrelations","volume":"171","author":"Jonuleit","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nature16141","article-title":"A mechanism for expansion of regulatory T-cell repertoire and its role in self-tolerance","volume":"528","author":"Feng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.108935_b0205","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0210","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00296-010-1728-3","article-title":"Identification, frequency, activation and function of CD4+ CD25(high)FoxP3+ regulatory T cells in children with juvenile idiopathic arthritis","volume":"32","author":"Stelmaszczyk-Emmel","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2022.108935_b0215","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/ni1437","article-title":"Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3","volume":"8","author":"Williams","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","article-title":"CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2","volume":"17","author":"Malek","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0225","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.4049\/jimmunol.169.9.4850","article-title":"Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers","volume":"169","author":"Almeida","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0230","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4049\/jimmunol.172.7.3983","article-title":"IL-2, regulatory T cells, and tolerance","volume":"172","author":"Nelson","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2007.08.005","article-title":"Interleukin-2 receptor signaling in regulatory T cell development and homeostasis","volume":"114","author":"Burchill","year":"2007","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2022.108935_b0240","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.immuni.2007.11.022","article-title":"Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire","volume":"28","author":"Burchill","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0245","first-page":"2521","article-title":"PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs","volume":"116","author":"Walsh","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2022.108935_b0250","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.108935_b0255","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.intimp.2022.108935_b0260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1084\/jem.20081242","article-title":"Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs","volume":"206","author":"Cruz-Guilloty","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2022.108935_b0265","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.18.1.275","article-title":"CD8+ T cell effector mechanisms in resistance to infection","volume":"18","author":"Harty","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0270","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2009.11.012","article-title":"Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells","volume":"32","author":"Pipkin","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0275","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.108935_b0280","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pep.2014.06.008","article-title":"High-level expression, purification and study of bioactivity of fusion protein M-IL-2((88)Arg, (125)Ala) in Pichia pastoris","volume":"101","author":"Li","year":"2014","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.intimp.2022.108935_b0285","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.108935_b0290","doi-asserted-by":"crossref","unstructured":"N. Arenas-Ramirez, C.P. Zou, S., D. Zingg, B. Brannetti, E. Wirth, T. Calzascia, J. Kovarik, L. Sommer, G. Zenke, J. Woytschak, C.H. Regnier, A. Katopodis, O. Boyman, Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2, Sci Transl Med 8 (2016) 367ra166. 10.1126\/scitranslmed.aag3187.","DOI":"10.1126\/scitranslmed.aag3187"},{"key":"10.1016\/j.intimp.2022.108935_b0295","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.immuni.2015.04.018","article-title":"Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps","volume":"42","author":"Mitra","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108935_b0300","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1109745","article-title":"The structure of interleukin-2 complexed with its alpha receptor","volume":"308","author":"Rickert","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.intimp.2022.108935_b0305","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003155","article-title":"Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate","volume":"10","author":"Merchant","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.intimp.2022.108935_b0310","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1038\/s41467-019-11782-w","article-title":"A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control","volume":"10","author":"Sun","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.108935_b0315","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1006\/jmbi.1994.0194","article-title":"The solution structure of the F42A mutant of human interleukin 2","volume":"247","author":"Mott","year":"1995","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.intimp.2022.108935_b0320","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/81199","article-title":"A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo","volume":"18","author":"Shanafelt","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2022.108935_b0325","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1445::AID-IMMU1445>3.0.CO;2-M","article-title":"IL-12 enhances IL-2 function by inducing CD25 expression through a p38 mitogen-activated protein kinase pathway","volume":"30","author":"Nguyen","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0330","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/cimm.1997.1220","article-title":"Partial signaling by cytokines: cytokine regulation of cell cycle and Fas-dependent, activation-induced death in CD4+ subsets","volume":"182","author":"Wang","year":"1997","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0335","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.4049\/jimmunol.1700433","article-title":"Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells","volume":"200","author":"Carmenate","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0340","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/CJI.0b013e3181b528da","article-title":"Engineered interleukin-2 antagonists for the inhibition of regulatory T cells","volume":"32","author":"Liu","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2022.108935_b0345","doi-asserted-by":"crossref","first-page":"10696","DOI":"10.1021\/bi050436x","article-title":"High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth","volume":"44","author":"Rao","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2022.108935_b0350","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41598-018-37280-5","article-title":"Directed evolution of super-secreted variants from phage-displayed human Interleukin-2","volume":"9","author":"Rojas","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.108935_b0355","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.2174\/092986610792231474","article-title":"Expression, purification, and characterization of a functional mutant recombinant human interleukin-2","volume":"17","author":"Liu","year":"2010","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.intimp.2022.108935_b0360","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s41419-018-1047-2","article-title":"A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2022.108935_b0365","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23852","article-title":"Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study","volume":"9","author":"Hartimath","year":"2018","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.intimp.2022.108935_b0370","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.V122.21.2278.2278","article-title":"Novel tumor-targeted, engineered IL-2 Variant (IL2v)-based immunocytokines for immunotherapy of cancer","volume":"122","author":"Klein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.108935_b0375","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.4049\/jimmunol.1201895","article-title":"Human IL-2 mutein with higher antitumor efficacy than wild type IL-2","volume":"190","author":"Carmenate","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0380","doi-asserted-by":"crossref","first-page":"e0264353","DOI":"10.1371\/journal.pone.0264353","article-title":"Human IL-2Ra subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach","volume":"17","author":"Beig Parikhani","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108935_b0385","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02303524","article-title":"Induction of lymphokine-activated killing with reduced secretion of interleukin-1\u03b2, tumor necrosis factor-\u03b1, and interferon-\u03b3 by interleukin-2 analogs","volume":"1","author":"Heaton","year":"1994","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.intimp.2022.108935_b0390","first-page":"2597","article-title":"Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy","volume":"53","author":"Ju","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2022.108935_b0395","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1073\/pnas.88.11.4636","article-title":"Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor","volume":"88","author":"Sauv\u00e9","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7738","key":"10.1016\/j.intimp.2022.108935_b0400","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.108935_b0405","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/protein\/gzg111","article-title":"Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity","volume":"16","author":"Rao","year":"2003","journal-title":"Protein Eng."},{"key":"10.1016\/j.intimp.2022.108935_b0410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1385\/ABAB:133:1:77","article-title":"Expression and purification of a mutant of human interleukin-2 in Pichia pastoris","volume":"133","author":"Liu","year":"2006","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.intimp.2022.108935_b0415","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1021\/bi00187a026","article-title":"Mutagenic analysis of a receptor contact site on interleukin-2: preparation of an IL-2 analog with increased potency","volume":"33","author":"Be Rndt","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.intimp.2022.108935_b0420","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1074\/jbc.275.10.6790","article-title":"Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog","volume":"275","author":"Fallon","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2022.108935_b0425","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0161-5890(03)00102-0","article-title":"Native and recombinant interleukin-2, two functionally distinct molecules","volume":"40","author":"Denis","year":"2003","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0430","first-page":"A102","article-title":"PS7:135 Amg 592 is an investigational il-2 mutein that induces highly selective expansion of regulatory t cells, Lupus","volume":"5","author":"Tchao","year":"2018","journal-title":"Science & Medicine"},{"key":"10.1016\/j.intimp.2022.108935_b0435","doi-asserted-by":"crossref","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2022.108935_b0440","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3389\/fimmu.2018.02905","article-title":"Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate","volume":"9","author":"Mortara","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2022.108935_b0445","doi-asserted-by":"crossref","first-page":"1913791","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2022.108935_b0450","doi-asserted-by":"crossref","first-page":"15373","DOI":"10.1038\/ncomms15373","article-title":"Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells","volume":"8","author":"Vazquez-Lombardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.108935_b0455","doi-asserted-by":"crossref","unstructured":"S.D. Gillies, Y. Lan, T. Hettmann, B. Brunkhorst, Y. Sun, S.O. Mueller, K.M. Lo, A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity, Clin Cancer Res 17 (2011) 3673\u20133685. 10.1158\/1078-0432.CCR-10-2921.","DOI":"10.1158\/1078-0432.CCR-10-2921"},{"key":"10.1016\/j.intimp.2022.108935_b0460","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12967-016-0910-0","article-title":"Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy","volume":"14","author":"Liu","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2022.108935_b0465","doi-asserted-by":"crossref","first-page":"12878","DOI":"10.1038\/ncomms12878","article-title":"Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy","volume":"7","author":"Ghasemi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.108935_b0470","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4049\/jimmunol.2000926","article-title":"Retargeting IL-2 signaling to NKG2D-expressing tumor-infiltrating leukocytes improves adoptive transfer immunotherapy","volume":"207","author":"Banerjee","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108935_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","article-title":"A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease","volume":"95","author":"Peterson","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2022.108935_b0480","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba5264","article-title":"An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice","volume":"5","author":"Khoryati","year":"2020","journal-title":"Sci. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:52:42Z","timestamp":1761587562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922004192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":96,"alternative-id":["S1567576922004192"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108935","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108935"}}